Influence of aggregation on immunogenici
β
Vivek S. Purohit; C. Russell Middaugh; Sathyamangalam V. Balasubramanian
π
Article
π
2006
π
John Wiley and Sons
π
English
β 221 KB
Recombinant human factor VIII (rFVIII), a multidomain glycoprotein is used in replacement therapy for treatment of hemophilia A. Unfortunately, 15%-30% of the treated patients develop inhibitory antibodies. The pathogenesis of antibody development is not completely understood. The presence of aggreg